Navigation Links
Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
Date:6/25/2009

emonstrated a safety profile consistent with previous studies of IPLEX(TM).

Based on the metabolic improvements observed in patients treated with IPLEX(TM) in this trial, and discussions with key opinion leaders, the Company intends to apply for a grant from the Muscular Dystrophy Association ("MDA") to facilitate an additional Phase II trial focused solely on a subset of MMD patients with severe insulin resistance who, based on the results of this trial, may be more likely to benefit from IPLEX(TM) treatment. Alternative methods of assessing muscle function will be considered for the proposed trial.

Dr. Melvin Sharoky, Insmed's Chairman, commented, "We are disappointed that this trial did not meet the majority of its functional endpoints. However, the statistically significant improvement in insulin sensitivity seen in this study suggests that an additional phase II study in MMD patients with severe insulin resistance may be warranted. We appreciate the MDA's financial support for the completed trial and look forward to the possibility of continuing to work with them."

Sharon Hesterlee, Senior Vice President and Executive Director of MDA Venture Philanthropy, said, "While the phase II clinical trial of IPLEX(TM) did not show efficacy in the overall MMD population in this trial, based on the data generated, we look forward to evaluating Insmed's grant application for a possible Phase II trial aimed at MMD patients with severe insulin resistance."

Dr. Sharoky continued, "IPLEX(TM) continues to demonstrate a strong safety profile and we believe it offers a potential treatment in multiple therapeutic areas, including Amyotrophic Lateral Sclerosis. Beyond IPLEX(TM), our current cash reserves of approximately $120 million provides us with a significant opportunity to continue growing our business through a variety of potential business development initiatives. We look forward to continuing to exp
'/>"/>

SOURCE Insmed Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Insmed CEO Resigns Due to Health Concerns
2. Insmed Announces First Quarter 2009 Financial Results
3. Insmed Regains NASDAQ Compliance
4. Insmed to Host First Quarter 2009 Conference Call
5. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
6. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
7. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
8. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
9. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
10. Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
11. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... , July 14, 2014 Cloud Pharmaceuticals, ... design and development, announced today the expansion of ... has been granted supercomputing time at Argonne National ... Through a discretionary allocation of ... Facility (ALCF), researchers at Cloud Pharmaceuticals will use ...
(Date:7/14/2014)... 2014 Throughout this past June ... clinical trials space, representing 38 countries globally, registered ... “Optimizing Patient Participation in Clinical Trials. Attract. Engage. ... internationally renowned R&D expert, Ken Getz, of Tufts ... Drug Development through Patient Centricity. , Throughout this ...
(Date:7/14/2014)... , July 14, 2014 Minerva Neurosciences (NASDAQ: ... of new therapies to treat neuropsychiatric diseases and disorders, ... been appointed vice president of finance and chief accounting ... is a senior executive with more than 20 years ... and life science companies. His background includes the management ...
(Date:7/14/2014)... 14, 2014 PatientCrossroads, pioneer ... announced that three PatientCrossroads-based patient registries—DuchenneConnect, for ... Syndrome International Registry; and the NephCure Kidney ... contracts by the Patient-Centered Outcomes Research Institute ... a new health data network called PCORnet: ...
Breaking Biology Technology:Cloud Pharmaceuticals Granted 1M Hours of Supercomputer Time to Target Orphan Diseases Including Malaria 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 2Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 3Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 4Optimizing Patient Participation in Clinical Trials: Attract. Engage. Retain. – eCongress eBox Archives Now Available 5Minerva Neurosciences Announces Appointment Of Frederick W. Ahlholm As VP Of Finance And Chief Accounting Officer 2PatientCrossroads Fuels Development of New National Clinical Research Network 2PatientCrossroads Fuels Development of New National Clinical Research Network 3
... , Most Basic Recommended Cecil Instrumentation: , ... 500 l loop , Fraction collector , Column ... : , Researchers need to understand ... protein expression in healthy and diseased cells. , Hence the ...
... reliable and accurate long-range PCR and RT-PCR , ... RT-PCR Kits provide dedicated and highly reliable solutions for long-range,amplification from genomic DNA and cDNA. ... , QIAGEN LongRange PCR ... Amplification of extremely long PCR products up to 40 kb DNA or,12.5 kb ...
... LOS ANGELES, CA (August 10, 2006) - DoveBid, Inc., ( http://www.dovebid.com ... auction and valuation services, announced , today it ... Exchange auction online, on August 15, 2006. The event marks a milestone ... practice, and is expected , to bring to-date ...
Cached Biology Technology:Semi Preparative Purification of Proteins 2QIAGEN LongRange PCR and 2Step RT-PCR Kits 2World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition 2World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition 3
(Date:7/14/2014)... 2014 How does oxygen control insect body size? What ... in the first issue of Current Opinion in Insect ... and more questions. , Current Opinion in Insect Science ... series. It is a review journal that aims to provide ... expanding volume of information published in the field of insect ...
(Date:7/14/2014)... The Biogerontology Research Foundation (BGRF), a UK-based charity ... challenges of a rapidly ageing population, hosted the ... 30th, with Aging Analytics, a company supporting financial ... , The speakers at the forum included: , ... Kong on ,Impact Investment to Advance Longevity Research, ...
(Date:7/14/2014)... discovery and description of Rhipidocyrtus muiri - a ... to represent a new genus and species. The long and ... is discussed in a recent paper published in the open ... male, and only known specimen of Rhipidocyrtus muiri , ... this it was transferred among several researchers in the early ...
Breaking Biology News(10 mins):BGRF hosts inaugural 21st Century Medicine Forum 2Serendipity at the Smithsonian: The 107-year journey of the beetle Rhipidocyrtus muiri 2Serendipity at the Smithsonian: The 107-year journey of the beetle Rhipidocyrtus muiri 3
... the National Institutes of Health will explore the role ... by NIH,s National Institute of Environmental Health Sciences (NIEHS), ... people more vulnerable to heat exposure; changing weather patterns; ... toxic chemicals; and the negative effects of climate change ...
... discovered in the 16-23 million years old sediments of the ... Helophorus sibiricus , a member of the water scavenger ... in Eurasia and reaches even North America. The species was ... based on specimens collected at Lake Baikal. It is aquatic ...
... 2011. In the central Arctic the proportion of old, thick ... largely consists of thin, one-year-old floes. This is one of ... Polar and Marine Research in the Helmholtz Association brought back ... The ship arrived at its home port of Bremerhaven ...
Cached Biology News:NIH launches research program to explore health effects from climate change 2NIH launches research program to explore health effects from climate change 3A living species of aquatic beetle found in 20-million-year-old sediments 2Young and thin instead of old and bulky 2Young and thin instead of old and bulky 3Young and thin instead of old and bulky 4
Immunogen: C terminus [VQLKRSKNDSKPYC] of cardiac elav-type RNA-binding protein (ETR-3) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Standard 2" and 3" Fiberboard Boxes can be sold separately or with 16, 25, 36, 49, 64, 81 or 100 cell dividers. Fiberboard boxes can also be ordered with corresponding freezer racks...
...
Luminometers...
Biology Products: